Inhibition of Akt pathways in the treatment of prostate cancer

  • Nelson E
  • Evans C
  • Mack P
 et al. 
  • 21

    Readers

    Mendeley users who have this article in their library.
  • 26

    Citations

    Citations of this article.

Abstract

Akt is a serine/threonine kinase mediating multiple intracellular pathways involved in prostate cancer (CaP) biology. Increased understanding of the molecular mechanisms of Akt activation and signaling have led to the development of an increasing number of Akt inhibitors. These biologic agents demonstrate activity against a wide range of cancers in preclinical studies. Clinical studies of Akt inhibition in CaP are in progress, including agents such as celecoxib, perifosine and genistein. How best to integrate Akt inhibitors with standard CaP therapy or select patients most likely to benefit is the subject of ongoing research.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • E. C. Nelson

  • C. P. Evans

  • P. C. Mack

  • R. W. Devere-White

  • P. N. Lara

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free